-

$undefined

N/A

(N/A)

MiNK Therapeutics NASDAQ:INKT MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY.

Location: | Website: www.minktherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

22.96M

Cash

9.314M

Avg Qtr Burn

-3.019M

Short % of Float

0.51%

Insider Ownership

74.65%

Institutional Own.

2.25%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AgenT-797 + botensilimab/balstilimab Details Gastroesophageal adenocarcinomas, Gastric cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AgenT-797 Details Virus-Induced Acute Respiratory Disease Syndrome	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AgenT-797 +/- pembrolizumab/nivolumab Details COVID-19, Acute respiratory distress syndrome, Solid tumor/s, Gastric cancer, Testicular cancer, Cancer, Non-small cell lung carcinoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AgenT-797 Details Graft-versus-host disease , Immune Disorders	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.